Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof

MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof

US Patent 11384137 · Granted Jul 12, 2022

Estimated economic value: $8,181,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of triplex CMV vaccine in CAR T cell therapy2025
Genetically stable recombinant modified vaccinia Ankara (RMVA) vaccines and meth2025
Multivalent Epstein-Barr virus-like particles and uses thereof2025
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy2024
Multivalent Kaposi sarcoma-associated herpesvirus-like particles and uses thereo2024
MVA vaccine for delivery of a UL128 complex and preventing CMV infection2024
MVA vaccine for delivery of a UL128 complex and preventing CMV infection2024
Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved sta2024
Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved sta2024
Multivalent Epstein-Barr virus-like particles and uses thereof2024
Expression system for expressing herpesvirus glycoprotein complexes2023
Expression system for expressing herpesvirus glycoprotein complexes2023